- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Dr. Loeb discusses future research on the association between plant-based diets and prostate cancer
"For one thing, we're really interested in looking at plant-based diets in patients who are at high genetic risk for prostate cancer," says Stacy Loeb, MD, MSc.
In this video, Stacy Loeb, MD, MSc, highlights potential future research based on her publication, “Association of plant-based diet index with quality of life in patients with prostate cancer,” which was presented at the 2023 ASCO Annual Meeting in Chicago, Illinois. Loeb is a professor of urology and population health at New York University Grossman School of Medicine in New York, New York.
Video Transcript:
We have a few different things planned. For one thing, we're really interested in looking at plant-based diets in patients who are at high genetic risk for prostate cancer. So, that's something that we definitely want to look at in the future. We're also really interested to look at more of the mechanism behind this. What kind of changes are happening in the microbiome, for example, that might be underlying some of the benefits that we're seeing with the plant-based diet. And then finally, just implementation. Unfortunately, in medical school, we just get very little training on nutrition. And, we're all really busy in clinic. So, it's hard to have enough time to do really intensive counseling on things like nutrition and physical activity. But patients really want to know this stuff, and it's really important, as we're seeing here, for their longevity and their functional outcomes. So, how do we get this information out there without causing more of a burden for busy doctors?
This transcription has been edited for clarity.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
